Diagnosis & Differentiation
Comprehensive analysis reveals prognostic gene set that could impacts the response to chemotherapy and immunotherapy outcomes in malignant pleural mesothelioma
Clinical and Experimental Medicine 2025 November 18 [Link] Jun Li, Hongye He, Yutao Zhang, Muhammad Salman Azhar, Yongxiang Wang Abstract Malignant pleural mesothelioma (MPM) is a rare but aggressive thoracic malignancy primarily linked to asbestos exposure. Despite advances in research, the prognosis of MPM remains poor, and there is a lack of efficient and precise…
Read MorePositron emission tomography/computed tomography in risk-factor-negative young female with malignant pleural mesothelioma: A case report and review of literature
World Journal of Clinical Cases 2025 November 16 [Link] Aikedan Aisikaer, Mo-Mo Sun, Jie Shen Abstract Background: Malignant pleural mesothelioma (MPM), a rare aggressive malignancy, is primarily caused by asbestos exposure. MPM typically affects older adults (median age, 76 years), is uncommon in those under age 50 years and shows male predominance. Based on the…
Read MoreMethylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies
Molecular Oncology 2025 November 14 [Link] Janah Vandenhoeck, Nele De Meulenaere, Thomas Vanpoucke, Joe Ibrahim, Dieter Peeters, Suresh Krishan Yogeswaran, Wen Wen, Paul Van Schil, Jeroen M H Hendriks, Jo Raskin, Jan van Meerbeeck, Guy Van Camp, Ken Op de Beeck Abstract Pleural mesothelioma (PM) is a rare and aggressive cancer that often requires multiple…
Read MoreMalignant pleural mesothelioma classification and survival prediction with CT imaging using ResNet
European Radiology 2025 October 30 [Link] Meng Zhou, Minghua Li, Qian Cao, Zhen Zhang, Leonard Wee, Andre Dekker, Ji Zhu, Haitao Jiang, Jiapeng Jiang, Xinyu Miao, Weimin Mao, Meng Yan, Hongyang Lu Abstract Objectives: This study aims to achieve accurate differentiation of malignant pleural mesothelioma (MPM) from metastatic pleural disease (MPD) and to predict the…
Read MorePD-L1 expression as a prognostic factor for postoperative outcomes in pleural mesothelioma
Translational Lung Cancer Research 2025 September 30 [Link] Masatoshi Kanayama, Takehiko Manabe, Katsuma Yoshimatsu, Yukiko Nemoto, Hiroki Matsumiya, Masataka Mori, Masaru Takenaka, Koji Kuroda, Fumihiro Tanaka Abstract Background: Pleural mesothelioma (PM) is an uncommon malignancy with a poor prognosis, even after surgical resection. Programmed death-ligand 1 (PD-L1) expression is a potential prognostic biomarker in various…
Read MoreFL496, an FL118-derived small molecule, induces growth inhibition, senescence, and apoptosis of malignant pleural mesothelioma (MPM) cells, and exhibits anti-MPM tumor efficacy strikingly superior to the pemetrexed-cisplatin combination
Journal of Experimental and Clinical Cancer Research 2025 October 21 [Link] Ieman A M Aljahdali, Xiang Ling, Wenjie Wu, Wenchao Wang, Dan Li, Renyuan Zhang, Emma Zhang, Aimee Stablewski, Rami Azrak, Qingyong Li, Fengzhi Li Abstract Background: Malignant pleural mesothelioma (MPM) responds poorly to chemotherapy and is a highly progressive malignancy with a median survival…
Read MoreFL496, an FL118-derived small molecule, induces growth inhibition, senescence, and apoptosis of malignant pleural mesothelioma (MPM) cells, and exhibits anti-MPM tumor efficacy strikingly superior to the pemetrexed-cisplatin combination
Journal of Experimental Clinical Cancer Research 2025 October 21 [Link] Ieman A M Aljahdali, Xiang Ling, Wenjie Wu, Wenchao Wang, Dan Li, Renyuan Zhang, Emma Zhang, Aimee Stablewski, Rami Azrak, Qingyong Li, Fengzhi Li Abstract Background: Malignant pleural mesothelioma (MPM) responds poorly to chemotherapy and is a highly progressive malignancy with a median survival time…
Read MoreApical Malignant Pleural Mesothelioma Presenting as Horner’s Syndrome: A Case Report
Cureus 2025 October 13 [Link] Shruthi Mankal, Chris Jacobs Abstract Horner’s syndrome is a well-recognized presentation of apical lung tumors, though rarely associated with malignant pleural mesothelioma (MPM), with only a few cases documented. We report the case of an 82-year-old man with persistent right-sided chest pain who developed unilateral right-sided ptosis, miosis and a…
Read MoreDiscovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma
Lung Cancer 2025 September 28 [Link] Jasper H L T van Genugten, Daniel Faulkner, Jens C Hahne, Charlotte Poile, Lodewyk Wessels, Dean A Fennell, Paul Baas Abstract Background: Malignant pleural mesothelioma (PM) is an aggressive cancer with limited treatment options. Although first-line nivolumab plus ipilimumab improves outcomes for some patients, a majority fail to respond.…
Read MoreManganese-doped nanotheranostic system for MRI-guided photothermal therapy of malignant pleural mesothelioma: in vivo study
Frontiers in Chemistry 2025 September 11 [Link] Lichang Lei, Hongjiao Zi, ShaoLei Kang, Hui Duan, Zhenghua Zhang, Chao Gao, Ruoyun Xu, Dan Han Abstract Introduction: Magnetic Resonance Imaging (MRI)-guided photothermal therapy (PTT) holds significant promise for the treatment of solid tumors, however, its diagnostic and therapeutic efficacy in malignant pleural mesothelioma (MPM) remains underexplored. To…
Read More
Skip to content